[9] LB1-03:Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study. SABCS 2024. [10] Martínez-Sáez O, Chic N, Pascual T...
[9]Komal J., Fabrice A., Erika H., et al. Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08).2023 SABCS. RF02-03. ...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. [19]https:/...
1、Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. Int J Clin Oncol. 2022 Feb;27(2):332-339. 2、Junji Tsurutani, et al. Subgroup Analysis of Patients ...
[3] Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metasta...
9、Hurvitz,Sara A et al.“Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer:updated results from DESTINY-Breast03,a randomised,open-label,phase 3 trial.”Lancet(London,England)vol.401,10371(2023):105-117.doi:10.1016/S0140-6736(22)02420-5...
11.Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane,...
[1] Venema, Clasina M et al. “Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.” Journal of nuclear medicine : official publication,Society of Nuclear Medicine vol. 58,12 (2017): 1906-1912. doi:10.2967/jnumed.117.193649 ...
2、Ma, Fei et al. “Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.” BMJ (Clinical research ed.) vol. 383 e076065. 31 Oct....
de Bernardi A, Bachelot T and Larrouquère L (2024) Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature. Front. Oncol. 13:1210873...